

PENINSULA UROLOGY CENTER NEWSLETTER

VOL: 1 ISSUE: 1 NOVEMBER 2005

A NOTE FROM DR. THREATT

Welcome to our first newsletter. The purpose of this newsletter is to inform the medical community of important issues in urology.

I would like to thank the physician community for all the new referrals and support in revitalizing Dr. Ritter's Peninsula Urology Center. I hope you and your patients have been happy with our delivery of patient care. We look forward to providing you with

new state of the art technologies and continued standards of care.

Each month we will bring to you a brief review of important topics in Urology to keep you abreast of changing practice patterns in the specialty, especially as they relate to managing your patients as primary care physicians.

CLINICAL STUDIES

Our clinical studies department headed by Linda McFeeters has started three new clinical studies investigating novel as well as current FDA approved medications for BPH and bladder dysfunction. We are actively enrolling patients, so if you know of anyone interested in clinical studies or a patient that would be a good candidate please give Linda a call at 650-306-0750. Linda along with Dr. Ritter performed the early clinical trial for Viagra, leading to FDA approval.

CONTINENCE CENTER

PUC is proud to announce that we have begun treating females in our continence center. Donna Losey, R.N. BSN MA has begun the pelvic muscle floor physical therapy training for females with bladder dysfunction. This is an excellent therapy for those who desire non pharmacological management of bladder issues and those with conditions refractory to medication.

Urodynamics is also being performed in the office for the evaluation of men and women with complex voiding dysfunction and patients requiring surgery.

MONTHLY TOPIC

In future issues we will be discussing our monthly topic in this area. Those of you who treat men with BPH will be happy to know that the Prolief microwave therapy has been a huge success in managing patients with progressive BPH disease refractory to pharmacotherapy. Of the 24 patients treated in office since March none have gone on to require a TURP. Many have required continued use of an alpha blocker but with a significant reduction in AUA index score.

UPCOMING TOPICS

1. BPH
2. Incontinence
3. Hematuria
4. Renal, Bladder, Prostate, Testicular Cancer
5. Kidney Stones
6. Interstitial Cystitis
7. Prostatitis And Chronic Pelvic Pain
8. Sterilization/vasectomy
9. Erectile Dysfunction
10. Male Menopause
11. Clinical Trials in Urology
12. Recurrent UTI's
13. Infertility